i8-k.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported):  June 25, 2009
 
INSMED INCORPORATED
(Exact Name of Registrant as Specified in Its Charter)
 
Virginia
(State or Other Jurisdiction of Incorporation)
 
0-30739
54-1972729
(Commission File Number)
(IRS Employer Identification No.)
       
8720 Stony Point Parkway, Suite 200, Richmond, Virginia
23235
(Address of Principal Executive Offices)
(Zip Code)
 
(804) 565-3000
(Registrant’s Telephone Number, Including Area Code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
    o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
    o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
    o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
    o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
INFORMATION TO BE INCLUDED IN THE REPORT

Section 8—Other Events
 
Item 8.01.
Other Events.
 
On June 25, 2009 Insmed Incorporated published a press release announcing the results for its Phase II clinical trial of IPLEX™ in the Myotonic Muscular Dystrophy indication.  A copy of the press release is attached hereto as Exhibit 99.1.
 
The information contained herein, including the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
 
Item 9.01.                                Financial Statements and Exhibits.
 
(d)           Exhibits
 
Exhibit No.                                           Description
 
99.1
Press Release issued by Insmed Incorporated on June 25, 2009
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Insmed Incorporated
   
   
Date: June 25, 2009
  
 
By:  /s/ Kevin P. Tully
 
Name:  Kevin P. Tully C.G.A.,
 
Title:  Executive Vice President & Chief Financial Officer
 
   
 
 
 
EXHIBIT INDEX

Exhibit No.                                           Description

99.1
Press Release issued by Insmed Incorporated on June 25, 2009